[1] Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials [J]. The Lancet, 1998, 351(9114): 1451-1467. [2] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. The Lancet, 2013, 381(9869): 805-816. [3] Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial [J]. Journal of the National Cancer Institute, 2001, 93(9): 684-690. [4] Goss P E, Ingle J N, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. 17[J]. Journal of the National Cancer Institute, 2005, 97(17): 1262-1271. [5] Goss P E, Ingle J N, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA. 17[J]. Journal of clinical oncology, 2007, 25(15): 2006-2011. [6] Mamounas E P, Jeong J H, Wickerham D L, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial[J]. Journal of Clinical Oncology, 2008, 26(12): 1965-1971. [7] Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. Journal of the National Cancer Institute, 2007, 99(24): 1845-1853. [8] Stewart H J, Prescott R J, Forrest A P M. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years[J]. Journal of the National Cancer Institute, 2001, 93(6): 456-462. [9] Tormey D C, Gray R, Falkson H C, et al. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer[J]. Journal of the National Cancer Institute, 1996, 88(24): 1828-1833. [10] Gray R G, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[C]//ASCO Annual Meeting Proceedings. 2013, 31(18_suppl): 5. [11] 韦小芳.内分泌治疗5年后继续强化治疗乳腺癌临床疗效的Meta分析[D].广西医科大学, 2012.
|